KMT2A and leukemia: To evaluate the importance of c-Myc expression, we treated MLL-FP cell lines with the BET inhibitor JQ1, which inhibits the proliferation of multiple forms of leukemia by disrupting BRD4 regulation of c-Myc [29-31] and other factors such as Myb and Ets proteins [32, 33].